First Pharmaceutical's new ADC cancer drug has been approved for clinical trials in China.

Market IntelThursday, Mar 6, 2025 8:41 am ET

1min read

On March 6, the National Medical Products Administration's (NMPA) Center for Drug Evaluation (CDE) officially announced that DSNKY.US's (First) 1st-class new drug DS-3939a was approved for clinical trials, and is intended to develop for the treatment of solid tumors. Public information shows that DS-3939a is an antibody-drug conjugate (ADC) targeting tumor-related MUC1, which is in the 1/2 phase clinical research stage worldwide. According to the CDE's website, this is the first time the product has been approved for clinical trials in China.The structure of the product consists of a humanized anti-TA-MUC1 antibody, an enzyme-cleavable tetrapeptide linker, and a DNA topoisomerase I inhibitor (DXd) with a high drug-antibody ratio (DAR). This innovative adc has been approved for clinical trials in China, indicating that it will enter the clinical research stage in China.

Disclaimer: the above is a summary showing certain market information. AInvest is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from a third party source. Communications displaying market prices, data and other information available in this post are meant for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.